Automatic bone scan index for therapy response assessment of radium-223-dichloride (Ra-223) therapy in advanced prostate cancer

被引：0
|
作者：
Sakretz, M. [1 ]
Kurth, J. [1 ]
Schwarzenboeck, S. M. [1 ]
Krause, B. J. [1 ]
Heuschkel, M. [1 ]
机构：
[1] Univ Rostock, Dept Nucl Med, Med Ctr, D-18055 Rostock, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P748
引用
收藏
页码：S699 / S699
页数：1
相关论文
共 50 条
  • [21] Hematotoxicity and non-hematological adverse events of Ra-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
    Ahmadzadehfar, Hojjat
    Azgomi, Kambiz
    Rogenhofer, Sebastian
    Bundschuh, Ralph
    Kuerpig, Stefan
    Essler, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [22] Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment—Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial
    Kazuhiro Kitajima
    Masataka Igeta
    Junpei Kuyama
    Takashi Kawahara
    Tsuyoshi Suga
    Tomoaki Otani
    Shigeyasu Sugawara
    Yumiko Kono
    Yukihisa Tamaki
    Ayumi Seko-Nitta
    Yoshinobu Ishiwata
    Kimiteru Ito
    Akira Toriihara
    Shiro Watanabe
    Makoto Hosono
    Hideaki Miyake
    Shingo Yamamoto
    Mitsuhiro Narita
    Takashi Daimon
    Koichiro Yamakado
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 1487 - 1498
  • [23] What is the clinical significance of a rising PSA during Ra-223 dichloride therapy?
    Wang, Jiaqiong
    Kuker, Russ
    Singal, Rakesh
    Serafini, Aldo
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [24] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
    Alonzi, Roberto
    Parker, Chris C.
    Tunariu, Nina
    Koh, Dow-Mu
    Staffurth, John
    Blackledge, Matthew D.
    Padhani, Anwar R.
    Tree, Alison
    Stidwill, Helen
    Finch, Jessica
    Chatfield, Peter
    Perry, Sophie
    Tovey, Holly
    Hall, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [26] Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and PSA in prostate cancer patients receiving radium-223 dichloride therapy.
    Nakagami, Y.
    Kano, D.
    Kusumoto, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S698 - S699
  • [27] A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).
    Sternberg, Cora N.
    Saad, Fred
    Graff, Julie Nicole
    Peer, Avivit
    Vaishampayan, Ulka N.
    Leung, Eugene
    Rosenbaum, Eli
    Gurney, Howard
    Epstein, Richard
    Davis, Ian D.
    Wu, Bingyan
    Trandafir, Lucia
    Wagner, Volker Jean
    Hussain, Maha
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial
    Kitajima, Kazuhiro
    Igeta, Masataka
    Kuyama, Junpei
    Kawahara, Takashi
    Suga, Tsuyoshi
    Otani, Tomoaki
    Sugawara, Shigeyasu
    Kono, Yumiko
    Tamaki, Yukihisa
    Seko-Nitta, Ayumi
    Ishiwata, Yoshinobu
    Ito, Kimiteru
    Toriihara, Akira
    Watanabe, Shiro
    Hosono, Makoto
    Miyake, Hideaki
    Yamamoto, Shingo
    Narita, Mitsuhiro
    Daimon, Takashi
    Yamakado, Koichiro
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (05) : 1487 - 1498
  • [29] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
    Finkelstein, S. E.
    Michalski, J. M.
    O'Sullivan, J.
    Parker, C.
    Garcia-Vargas, J.
    Sartor, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
  • [30] Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial
    Parker, Christopher
    Zhan, Lin
    Cislo, Paul
    Reuning-Scherer, Jonathan
    Vogelzang, Nicholas J.
    Nilsson, Sten
    Sartor, Oliver
    O'Sullivan, Joe M.
    Coleman, Robert E.
    EUROPEAN JOURNAL OF CANCER, 2017, 71 : 1 - 6
12345